Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
CAMBRIDGE, Mass., May 08, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in May. Details are as follows:
Bank of America Merrill Lynch 2017 Health Care Conference
| Date: | Wednesday, May 17, 2017 | ||
| Forum: | Panel Discussion on Gene Therapy and Gene Editing | ||
| Time: | 4:40 p.m. ET | ||
| Location: | Las Vegas |
UBS Global Healthcare Conference
| Date: | Monday, May 22, 2017 | ||
| Forum: | Company Presentation and Breakout Session | ||
| Time: | 8:00 a.m. ET | ||
| Location: | New York |
A live webcast of the presentation will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Cristi Barnett Editas Medicine, Inc. (617) 401-0113 [email protected] Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
